Free-standing non-fouling polymers and polymeric compositions, monomers and macromonomers for making the polymers and polymeric compositions, objects made from the polymers and polymeric compositions, and methods for making and using the polymers and polymeric compositions.

Free-standing non-fouling polymers and polymeric compositions, monomers and macromonomers for making the polymers and polymeric compositions, objects made from the polymers and polymeric compositions, and methods for making and using the polymers and polymeric compositions.

The present invention is directed towards a process for manufacturing a complexing agent, said process comprising the steps of (a) Providing a nitrile according to general formula (I a) or (I b) ##STR00001## With M being selected from alkali metal and hydrogen and combinations thereof, (b) Saponification with a total alkali amount of 2.5 to 2.9 mol of alkali metal hydroxide per mole of nitrile according to general formula (I a) or (I b), respectively, and a pH value in the range of from 9.5 to 11.5 at the end of step (b), (c) Adding an amount of alkali metal hydroxide so that the total alkali content is 2.9 to 3.15 moles per mole nitrile according to general formula (I a) or (I b), respectively, and (d) Allowing further conversion.

The present invention is directed towards a process for manufacturing a complexing agent, said process comprising the steps of (a) Providing a nitrile according to general formula (I a) or (I b) ##STR00001## With M being selected from alkali metal and hydrogen and combinations thereof, (b) Saponification with a total alkali amount of 2.5 to 2.9 mol of alkali metal hydroxide per mole of nitrile according to general formula (I a) or (I b), respectively, and a pH value in the range of from 9.5 to 11.5 at the end of step (b), (c) Adding an amount of alkali metal hydroxide so that the total alkali content is 2.9 to 3.15 moles per mole nitrile according to general formula (I a) or (I b), respectively, and (d) Allowing further conversion.

The present invention is directed towards a process for manufacturing a complexing agent, said process comprising the steps of (a) Providing a nitrile according to general formula (I a) or (I b) ##STR00001## With M being selected from alkali metal and hydrogen and combinations thereof, (b) Saponification with a total alkali amount of 2.5 to 2.9 mol of alkali metal hydroxide per mole of nitrile according to general formula (I a) or (I b), respectively, and a pH value in the range of from 9.5 to 11.5 at the end of step (b), (c) Adding an amount of alkali metal hydroxide so that the total alkali content is 2.9 to 3.15 moles per mole nitrile according to general formula (I a) or (I b), respectively, and (d) Allowing further conversion.

Process for making solid methylglycine diacetate (MGDA) alkali metal salt (A), said process comprising the steps of (a) providing a 40 to 60% by weight aqueous solution of said salt (A) having a temperature in the range of from 50 to 90° C., (b) crystallizing salt (A), (c) removing said crystalline salt (A) from the mother liquor by filtration, and (d) subjecting the water containing filter cake from step (c) to an extrusion step.

Process for making solid methylglycine diacetate (MGDA) alkali metal salt (A), said process comprising the steps of (a) providing a 40 to 60% by weight aqueous solution of said salt (A) having a temperature in the range of from 50 to 90° C., (b) crystallizing salt (A), (c) removing said crystalline salt (A) from the mother liquor by filtration, and (d) subjecting the water containing filter cake from step (c) to an extrusion step.

Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) ##STR00001##
including stereoisomers and pharmaceutically acceptable salts thereof, wherein R.sup.1a, R.sup.1b, R.sup.1c, R.sup.1d, R.sup.2a, R.sup.2b, R.sup.3, R.sup.3a, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8 and the subscript n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) ##STR00001##
including stereoisomers and pharmaceutically acceptable salts thereof, wherein R.sup.1a, R.sup.1b, R.sup.1c, R.sup.1d, R.sup.2a, R.sup.2b, R.sup.3, R.sup.3a, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8 and the subscript n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

The present invention belongs to the technical field of gene therapy, and particularly relates to a series of lipid compounds as well as a lipid carrier, nucleic acid lipid nanoparticle composition and pharmaceutical preparation containing the same. A compound having a structure of a formula (I) provided by the present invention can be used for preparing a lipid carrier together with other lipid compounds, and exhibits pH response, and the entrapment efficiency to a nucleic acid drug is high, which greatly improves in-vivo delivery efficiency of the nucleic acid drug; and furthermore, a lipid compound with a specific structure can be chosen as a lipid carrier based on an organ in which the nucleic acid drug needs to be enriched, having a good market application prospect.